메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

UNSW and NeuRA Lead New Study to Explore How ReNeuWell® App Supports Mental Wellbeing

SYDNEY, Sept. 4, 2025 -- A clinical trial is being launched by researchers from UNSW and Neuroscience Research Australian (NeuRA) for a new app called ReNeuWell®, based on a scientifically validated measure of wellbeing. The application has been designed in collaboration with a research team led by A/Professor Justine Gatt from UNSW's School of Psychology and NeuRA. It uses the COMPAS-W Wellbeing Scale - which measures both subjective and psychological wellbeing, a scale developed by A/Prof Justine Gatt and that has been validated in neuroscience. Miroma Project Factory, sp
- 김갑성 기자
- 2025-09-04 06:23
Illumina® Protein Prep launches to drive greater proteomic insights for improved drug discovery and development

[ 메디채널 김갑성 기자 ] Illumina Protein Prep can measure 9500 unique human protein targets, offering new insights into protein biology to fuel novel discovery for treatment of disease Following early access program, customers commend scale, high consistency, and easy sample to insights workflow Launch follows Illumina's announcement of agreement to acquire SomaLogic SAN DIEGO, Sept. 3, 2025 -- Illumina Inc. (NASDAQ: ILMN) today announced the launch of Illumina Protein Prep, an assay introducing superior performance for next-generation sequencing (NGS) based proteomics discove
- 김갑성 기자
- 2025-09-03 21:15
SPS Expands Philips SpeechLive with Ambient Medical AI Documentation, Powered by Corti

VIENNA, Austria and COPENHAGEN, Denmark, Sept. 3, 2025 -- Speech Processing Solutions (SPS), the global leader behind Philips SpeechLive, today announced a strategic partnership with Corti, the specialized AI infrastructure company for healthcare, to introduce ambient clinical documentation directly into the SpeechLive platform. This partnership integrates Corti's real-time medical reasoning engine into the SpeechLive AI Assistant - transforming the trusted dictation platform into a fully AI-powered documentation ecosystem. As the only platform that brings together dictation, s
- 김갑성 기자
- 2025-09-03 20:53
Global Bio Conference 2025 kicks off in Seoul, charting biotech's future

SEOUL, South Korea, Sept. 3, 2025 -- This is an article published in The Korea Herald: The Ministry of Food and Drug Safety announced Wednesday that it kicked off Global Bio Conference 2025, under the theme "Bio, Navigating Infinite Possibilities." The conference will be held from Wednesday to Friday at the Grand InterContinental Seoul Parnas in southern Seoul. Celebrating its 11th year, GBC has established itself as a leading global platform, bringing together approximately 5,000 participants each year from regulatory authorities, the pharmaceutical industry a
- 김갑성 기자
- 2025-09-03 20:00
Acer Expands SpatialLabs Pro Ecosystem with Immersive 3D Capabilities Across Multiple Verticals

Editor's Summary Integration with NVIDIA Omniverse libraries via OpenXR runtime supports enhanced spatial awareness for industrial designs and simulations Partnership with Video Engineering brings 3D stereo microscopy to inspection, design, and prototyping workflows Collaboration with Smart Surgery for medical training allows for high-resolution, glasses-free analysis on SpatialLabs' 3D displays BERLIN, Sept. 3, 2025 -- Acer today announced significant advancements in its SpatialLabs™ Pro solution, unveiling new integrations with NVIDIA Omniverse, Video Engineer
- 김갑성 기자
- 2025-09-03 17:40
Acer Medical Unveils aiMed Ahead of IFA 2025, Showcasing the Future of AI in Healthcare

BERLIN, Sept. 3, 2025 -- Acer Medical, an Acer Group company specializing in medical imaging and AI-powered healthcare solutions, unveiled aiMed, its next-generation generative AI medical documentation system at the next@acer global press conference, ahead of IFA 2025 in Berlin. The milestone underscores Acer Medical's expanding global footprint and its commitment to transforming healthcare through AI and digital innovation. aiMed directly addresses one of the most pressing challenges in modern healthcare —clinical documentation overload. On average, healthcare providers spend up to 25
- 김갑성 기자
- 2025-09-03 17:30
Smartee Launches Early Orthodontic Solutions for Children and Teens in Australia

SYDNEY, Sept. 2, 2025 -- Smartee Denti-Technology, a global leader in innovative clear aligner solutions, has officially launched its clear aligner products for children and teenagers in Australia. The product lines include Smartee Kinder and Smartee Teen, are designed to address the unique orthodontic challenges of growing patients at different developmental stages. Market Insights: Pediatric Orthodontics in Australia In Australia, pediatric orthodontic care is delivered through three main practitioner groups: orthodontic specialists, pediatric dentists, and general pra
- 김갑성 기자
- 2025-09-03 16:26
DeepQure Strengthens Clinical Leadership with Former SoniVie Executive Appointment

SEOUL, South Korea, Sept. 3, 2025 -- DeepQure, a company pioneering a paradigm shift in hypertension treatment, today announced the appointment of Jason G. Jones as Global Vice President of Clinical & Regulatory Affairs. Jason joins DeepQure from SoniVie, an Israeli company developing catheter-based intravascular ultrasound renal denervation (RDN) treatment that was acquired by Boston Scientific for $540 million in March 2025. At SoniVie, he led the global clinical development strategy and clinical operations activities at the company. Jason oversaw the completion of enrollment for
- 김갑성 기자
- 2025-09-03 10:52
US Food and Drug Administration (FDA) Approves Henlius and Organon's BILDYOS® (denosumab-nxxp) and BILPREVDA® (denosumab-nxxp), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively

SHANGHAI and JERSEY CITY, N.J., Sept. 2, 2025 -- Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the US Food and Drug Administration (FDA) has approved BILDYOS® (denosumab-nxxp) injection 60 mg/mL and BILPREVDA® (denosumab-nxxp) injection 120 mg/1.7 mL, biosimilars to PROLIA (denosumab) and XGEVA (denosumab), respectively, for all indications of the reference products.1,2 "The FDA approvals of BILDYOS and BILPREVDA mark a significant step toward expanding access to critical bone care treatments needed by millions of people in the US, inclu
- 김갑성 기자
- 2025-09-02 21:10
Seegene and Springer Nature Open Applications for 2025-2026 Nature Awards MDx Impact Grants

- The program focuses on antibiotic resistance in urinary tract infections (UTI-DR), with applications open until November 20; final awardees to be announced in August 2026- Selected researchers will receive up to USD 600,000 in research funding, along with access to Seegene's syndromic PCR assays, instruments, and software- Program aims to advance Seegene's Technology-Sharing Initiative and expand access to molecular diagnostics SEOUL, South Korea, Sept. 2, 2025 -- Seegene Inc., a global leader in molecular diagnostics, announced today the launch of the 20
- 김갑성 기자
- 2025-09-02 21:00

이전

1 2 3 4 5 6 7 8 9 10

많이 본 기사

최근기사

2025-09-04_THU

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 09월 04일 12시 20분